Últimas noticias sobre Baosheng Media Gr (NASDAQ:BAOS) Bolsa

Baosheng Media Gr

Baosheng Media Group Holdings Ltd operates as a V-log streaming marketing service provider. The firm offers comprehensive marketing solutions. Its services are Internet effect marketing, V-log or short video streaming marketing including content production and operation, e-commerce marketing, original data platform system service, and AI technology. It provides one-stop and full-link deep customized marketing solutions for partners. Baosheng Group is also a core agency of domestic Internet companies such as Tencent, Alibaba, Bytedance, and Kuaishou, with performing channel marketing services, technologies, and applications.

Baosheng Media Group Holdings Limited - Ordinary shares

Baosheng Media Group Holdings Ltd

Regulatory Approval by the UK Financial Conduct Authority was Key Requirement for Transaction Timing
Minimal Conditions Remain for Deal Completion; Closing Expected in July, 2025
&nbsp;Interactive Strength Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRNR#NASDAQ">TRNR</a>) ("TRNR" or the "Company") today announced that it has received formal approval from the UK Financial Conduct Authority ("FCA") for its previously-announced acquisition of Wattbike, the UK-based, omni-channel, connected, indoor-performance bike business, and that it expects to complete the acquisition in July, 2025.
The FCA's approval satisfies a key condition for the closing of the acquisition, which is expected to significantly expand Interactive Strength Inc.'s presence in the global fitness market, particularly in the UK, and enhance its product offerings with a leading indoor-performance bike offering. This strategic acquisition is anticipated to be immediately accretive to TRNR's results and accelerate growth, especially in key markets like the US and Germany, leveraging TRNR's global distribution network.
Wattbike delivered over $15 million in 2024 revenue and has built on its prestigious elite-sport base - including Olympic teams, Premier League clubs, major US sports teams and elite fitness facilities - to debut a much broader product portfolio that will allow its footprint to scale internationally as well as in the UK, its home market.
"We have been waiting to secure FCA approval in order to finalize the Wattbike deal and now we will push to completion quickly," said Trent Ward, Founder &amp; CEO of Interactive Strength. "This regulatory hurdle was the main closing requirement the timing of which we did not control. The remaining steps are largely administrative. We're already well underway integrating and collaborating with Wattbike, and we look forward to accelerating from here. Wattbike's elite heritage, combined with TRNR's Nasdaq listing, US distribution reach, and marketing muscle, positions us to drive meaningful growth across the UK, US, and Germany."
"We remain thrilled to become part of the TRNR family," added Stephen Loftus, CEO of Wattbike. "With FCA approval secured, we're on the road to fully leverage TRNR's global platform to accelerate our consumer and commercial expansion and bring premium, data-driven indoor cycling to new audiences."
Wattbike is renowned for its high-performance connected indoor bikes, with deep penetration into leading UK gyms and an expanding direct-to-consumer customer base. The acquisition consideration is structured as an all-stock transaction for 100% of Wattbike, and there is an earn-out component to align the business' financial performance with TRNR valuation. Further details regarding the financial impact of the acquisition will be provided in our upcoming filings with the U.S. Securities and Exchange Commission.

News

TRNR

Interactive Strength Announces It Has Received Formal Approval From The UK Financial Conduct Authority For Previously-Announced Acquisition Of Wattbike And Expects To Complete The Acquisition In July, 2025

Biotech

General

AEMD

Aethlon Medical Treats The Second Patient In Its Australian Hemopurifier Cancer Trial

Ancora Holdings Group, LLC (together with its affiliates, "Ancora" or "we") today issued the below statement following its decision to redeem its investment in the long-term special purpose vehicle managed by Hestia Capital Management LLC and, in turn, start directly holding its shares of Pitney Bowes Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBI#NYSE">PBI</a>) ("Pitney Bowes" or the "Company") due to the size of the position.
Fredrick D. DiSanto, Chairman and Chief Executive Officer of Ancora Holdings Group LLC, and James Chadwick, President of Ancora Alternatives LLC, commented:
"We originally invested in Kurt Wolf's special purpose vehicle because we believed Kurt could be a catalyst of significant value creation at Pitney Bowes. More than two years later, Kurt has clearly been the driving force behind the Company's cost reductions, cash repatriation initiatives, debt reduction and the necessary divestiture of the Global Ecommerce unit. The excellent results speak for themselves. We look forward to remaining long term investors in Pitney Bowes and believe shareholders are well served by Kurt Wolf as the Company's Chief Executive Officer."

Ancora Redeems Investment In Hestia Special Purpose Vehicle, Now Directly Holding Pitney Bowes Shares

Guidance

STLD

Steel Dynamics Sees Q2 EPS $2.00-$2.04

85% remission rate observed in evaluable frontline AML patients
Mipletamig combination enables rare pathway to transplant in a previously ineligible unfit patient
No dose-limiting toxicities observed among evaluable patients; safety profile remains strong
Evidence mounts for mipletamig as a potentially transformational addition to standard of care in frontline AML as targeted CD123 x CD3 approach showing power and precision, limited added toxicity
Mipletamig Trial Momentum Builds as Cohort 3 Nears Full Enrollment at highest dose level evaluated to date in combination therapy
SEATTLE, WA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / June 18, 2025 / Aptevo Therapeutics ("Aptevo") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>), a clinical-stage biotechnology company developing novel bispecific immuno-oncology therapeutics based on its proprietary ADAPTIR&#xAE; and ADAPTIR-FLEX&#xAE; platform technologies, today announced new clinical data from its ongoing Phase 1b/2 RAINIER trial evaluating mipletamig, its first-in-class CD123 x CD3 bispecific antibody, in combination with standard-of-care venetoclax and azacitidine (ven/aza) for newly diagnosed patients with acute myeloid leukemia (AML) who are unfit for intensive chemotherapy.
Across two trials, the mipletamig triplet therapy delivered remissions in 85% of evaluable frontline AML patients-which significantly exceeds results from competitor studies, including those achieved in the Viale A trial that evaluatedvenetoclax and azacitidine (ven/aza) as doublet therapy. These updated results from the RAINIER dose expansion trial continue to demonstrate a compelling efficacy advantage alongside a strong safety profile. No cytokine release syndrome (CRS) was observed in either cohorts 1 or 2. Cohort 3 Nears Full Enrollment at highest dose level evaluated to date in combination therapy.

APVO

Aptevo Therapeutics Reports 85% Remission Rate In Frontline AML With Mipletamig Combination, No Dose-Limiting Toxicities, Enables Transplant In Previously Ineligible Patient; Advances High-Dose Cohort Enrollment In RAINIER Trial

TruGolf Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUG#NASDAQ">TRUG</a>), a leading provider of golf simulator software and hardware, today announced that it filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-50 reverse stock split of its Class A common stock. The reverse stock split will take effect at 12:01 am (Eastern Time) on June 23, 2025, and the Company's Class A common stock will open for trading on The Nasdaq Capital Market on June 23, 2025 on a post-split basis, under the existing ticker symbol "TRUG" but with a new CUSIP number 243733409.
As a result of the reverse stock split, every fifty shares of the Company's Class A common stock issued and outstanding prior to the opening of trading on June 23, 2025 will be consolidated into one issued and outstanding share. Proportionate adjustments will be made to the exercise prices and the number of shares underlying the Company's outstanding equity awards, as applicable, as well as to the number of shares issuable under the Company's equity incentive plans. The Class A common stock issued pursuant to the reverse stock split will remain fully paid and non-assessable. The reverse stock split will not affect the number of authorized shares of Class A common stock or the par value of the Class A common stock. No fractional shares will be issued if, as a result of the reverse stock split, a stockholder would become entitled to a fractional share because the number of shares of Class A common stock they hold before the reverse stock split is not evenly divisible by the split ratio. Instead, the stockholder will be entitled to receive a cash payment in lieu of a fractional share.

Stock Split

TRUG

TruGolf Announces A 1-For-50 Reverse Stock Split, Effective June 23, 2025

Euroseas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESEA#NASDAQ">ESEA</a>) reported quarterly earnings of $3.76 per share which beat the analyst consensus estimate of $3.28 by 14.63 percent. This is a 41.35 percent increase over earnings of $2.66 per share from the same period last year. The company reported quarterly sales of $56.35 million which beat the analyst consensus estimate of $52.91 million by 6.49 percent. This is a 20.61 percent increase over sales of $46.72 million the same period last year.

Earnings

Earnings Beats

ESEA

Euroseas Q1 Adj. EPS $3.76 Beats $3.28 Estimate, Sales $56.35M Beat $52.91M Estimate

Intelligent Bio Solutions Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INBS#NASDAQ">INBS</a>) on Wednesday announced that Managed Waste Service plans to implement INBS' Intelligent Fingerprinting Drug Screening System across its New South Wales operations, including its land clearing and <a href="https://www.benzinga.com/exclusives" target="_blank" rel="noreferrer noopener">green waste processing sites</a>.
Managed Waste Service is an Australia-based waste management provider.
The decision marks Managed Waste Service's first move into in-house drug testing across multiple locations. More than 20 sites are engaged in remote testing operations.
Managed Waste Service plans to conduct pre-employment, random, and for-cause testing on-site, giving operational teams complete control over safety processes without the disruption associated with traditional outsourced models.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/05/45372843/exclusive-intelligent-bio-solutions-q3-gross-profit-jumps-by-91" rel="noreferrer noopener">EXCLUSIVE: Intelligent Bio Solutions Q3 Gross Profit Jumps By 91%</a>
<h2 class="wp-block-heading">Why It Matters</h2>
The Intelligent Fingerprinting Drug Screening System offers a quick, noninvasive method of screening for recent drug use through fingerprint sweat analysis, delivering results in under ten minutes.
Intelligent Bio Solutions' technology enables Managed Waste Service to implement a scalable, portable solution that aligns with the nature of their fieldwork, whether testing at a remote clearing site or managing compliance across several waste facilities simultaneously.
This implementation reflects Intelligent Bio Solutions' continued expansion into safety-critical industries, with environmental services now joining a growing portfolio of sectors adopting sweat-based drug testing.
Intelligent Bio Solutions provides drug testing.
Over 450 organizations in 24 countries use its technology to streamline and simplify workplace testing.
In June, SMARTOX, a U.S.-based provider of drug and alcohol testing products and services, said it deployed over 50 Intelligent Fingerprinting Drug Screening Readers and facilitated over 7,000 screening tests, including over 1,500 tests <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45880764/exclusive-intelligent-bio-solutions-expands-us-forensic-market-presence-seeks-fda-clearance-for-fingerprint-drug-testing" rel="noreferrer noopener">in 2024 alone</a>.
As adoption grows in the U.S. Forensic Use Only market, Intelligent Bio continues to actively pursue FDA clearance for its opiate test system for codeine.
This effort aims to enable expansion into broader U.S. markets this year, including workplace drug testing, using its innovative fingerprint sweat-based testing technology.
Price Action: INBS stock is up 1.55% at $1.96 during the premarket session at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/fda/25/06/45982666/fda-introduces-tumor-board-style-reviews-for-faster-drug-decisions" target="_blank" rel="noreferrer noopener">FDA Introduces Tumor Board-Style Reviews For Faster Drug Decisions</a></li>
</ul>

Health Care

Market-Moving Exclusives

Exclusives

Intelligent Bio Solutions Inc. - Common Stock

INBS

EXCLUSIVE: Intelligent Bio's Fingerprint Drug Testing Gains Momentum With New Australian Rollout

Houston American Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUSA#NYSE">HUSA</a>) (the "Company") today announced that it has entered into a definitive agreement with an institutional investor (the "SPA") for the purchase and sale of an aggregate of 223,762 shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $10.60 per share (or pre-funded warrant in lieu thereof) in a registered direct offering (the "Offering").&nbsp;
The aggregate gross proceeds to the Company of this offering are expected to be approximately $2.37 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The Company currently intends to use the net proceeds of approximately $2.1 million from the offering for general corporate purposes. The transaction is expected to close on or about June 20, 2025, subject to the satisfaction of customary closing conditions.
The registered direct offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-282778) previously filed by the Company and declared effective by the U.S. Securities and Exchange Commission ("SEC") on November 4, 2024. A final prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC's website located at&nbsp;<a href="https://www.globenewswire.com/Tracker?data=ipYweY8yDlYW-qqz57KHaMXnT5UB-_uBTxUfMYPzzTjpIB7x8gbB_XCOM_DSKnvKHKmu6GqquCd8X7sSrtLfwkaScVa3rubTeU3dhJjXhTzFxQEu5El5LbgIQb3TLqwqXKXXfUrTEzkS-mn_jPuPCsKjqq6FprIlvviuGeq3F_2Zd-y1ZZd_qy470Z4Vmr7-hj229CfljPcnf4qPdC0CtBrWU43TmKoBBPLEVIFOjpU=">http://www.sec.gov</a>.&nbsp;Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained, when available, by contacting Univest Securities, LLC at&nbsp;<a href="https://www.globenewswire.com/Tracker?data=vQlj2dzieGJnl9zkACn2STIMZh6eFT3yho1nyxzdXON4o1eqshyKf9YE3RESVTAjypuzN6sC7Dk_muYtDEDaoHtwlFdsL-_1Xnv79VdbRUag_BZA6iYZd0SctZf4fxMwc7UEQ9c9nghwQPMRRvec04BEJkdHhjtEc0ArZXLV5pAhH73bg5fpARr61DoCVttgSsn38G5Hmrik-vSmFiaywka6HocZylUCfOGwiBK-1Ss=">info@univest.us</a>,&nbsp;or by calling +1 (212) 343-8888.

Offerings

HUSA

Houston American Energy Corp Announces A Registered Direct Offering Of $2.37M At A Purchase Price Of $10.60 Per Share

Alkami Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKT#NASDAQ">ALKT</a>) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $39.4, a high estimate of $46.00, and a low estimate of $30.00. This current average represents a 13.22% decrease from the previous average price target of $45.40. 
<img src="https://www.benzinga.com/files/images/story/2025/1750248102_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Alkami Technology. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ella Smith</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$40.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Jacob Stephan</td>
<td>Lake Street</td>
<td>Lowers</td>
<td>Buy</td>
<td>$41.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$46.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Mayank Tandon</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$40.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Saket Kalia</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$30.00</td>
<td>$35.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Alkami Technology. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Alkami Technology compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Alkami Technology's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Alkami Technology's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ALKT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Alkami Technology analyst ratings.</a>
<h2>About Alkami Technology</h2>
Alkami Technology Inc is a cloud-based digital banking solutions provider. The company's solution, the Alkami Digital Banking Platform, allows FIs to onboard and engage new users, accelerate revenues and meaningfully improve operational efficiency, all with the support of a proprietary, true cloud-based, multi-tenant architecture.
<h3>Unraveling the Financial Story of Alkami Technology</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Alkami Technology's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 28.52%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: Alkami Technology's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -7.99% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Alkami Technology's ROE stands out, surpassing industry averages. With an impressive ROE of -2.26%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Alkami Technology's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -1.23%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.24.
<h2>Analyst Ratings: Simplified</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

ALKT

Assessing Alkami Technology: Insights From 5 Financial Analysts

Earnings Misses

LiveOne Q4 EPS $(0.08) Misses $(0.04) Estimate, Sales $19.29M Miss $22.26M Estimate

In the last three months, 20 analysts have published ratings on Ralph Lauren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RL#NYSE">RL</a>), offering a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">8</td>
<td align="right">9</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Ralph Lauren, revealing an average target of $297.8, a high estimate of $384.00, and a low estimate of $205.00. Marking an increase of 4.13%, the current average surpasses the previous average price target of $286.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1750248044_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of Ralph Lauren by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$315.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$384.00</td>
<td>$335.00</td>
</tr>
<tr>
<td>Heather Balsky</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$328.00</td>
<td>$318.00</td>
</tr>
<tr>
<td>Brooke Roach</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$324.00</td>
<td>$262.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$300.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$295.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Simeon Siegel</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Underperform</td>
<td>$205.00</td>
<td>$197.00</td>
</tr>
<tr>
<td>Adrienne Yih</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$321.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Ashley Helgans</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$328.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$315.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>Tom Nikic</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$310.00</td>
<td>$310.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$315.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$315.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>Tom Nikic</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$310.00</td>
<td>$310.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$275.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$335.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Adrienne Yih</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$260.00</td>
<td>$310.00</td>
</tr>
<tr>
<td>Brooke Roach</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$262.00</td>
<td>$286.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$240.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$219.00</td>
<td>$282.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Ralph Lauren. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Ralph Lauren compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Ralph Lauren's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Ralph Lauren's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Ralph Lauren analyst ratings.</a>
<h2>Get to Know Ralph Lauren Better</h2>
Founded by designer Ralph Lauren in 1967 in New York City, Ralph Lauren Corp. designs, markets, and distributes lifestyle merchandise in North America, Europe, and Asia. Best known for its iconic polo shirts, its products also include other types of apparel, footwear, eyewear, jewelry, handbags, home goods, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, and Lauren Ralph Lauren. Distribution channels for Ralph Lauren include wholesale (department stores and specialty stores), retail (company-owned retail stores and e-commerce), and licensing.
<h3>Understanding the Numbers: Ralph Lauren's Finances</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Positive Revenue Trend: Examining Ralph Lauren's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 8.25% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 7.6%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Ralph Lauren's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.03% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.83%, the company showcases effective utilization of assets.
Debt Management: Ralph Lauren's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.03.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 20 Analyst Ratings Have To Say About Ralph Lauren

EXCLUSIVE: Intelligent Bio Solutions Tells Benzinga Co. Launches In-House Fingerprint Drug Testing Across 20+ Sites Major Australian Waste Operator, Says Accelerating APAC Expansion

HC Wainwright &amp; Co. analyst Joseph Pantginis assumes Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Buy rating and announces Price Target of $41.

Price Target

Initiation

CDTX

HC Wainwright & Co. Assumes Cidara Therapeutics at Buy, Announces Price Target of $41

HC Wainwright &amp; Co. analyst Mitchell Kapoor downgrades Verve Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>) from Buy to Neutral and maintains the price target from $13.5 to $13.5.

Downgrades

VERV

HC Wainwright & Co. Downgrades Verve Therapeutics to Neutral, Maintains Price Target to $13.5

Barrington Research analyst Gary Prestopino maintains Stoneridge (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRI#NYSE">SRI</a>) with a Outperform and maintains $16 price target.

Barrington Research Maintains Outperform on Stoneridge, Maintains $16 Price Target

Prenetics Global Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>) ("Prenetics"), a leading consumer health sciences company, today announced it has entered into a definitive agreement to divest its ownership in ACT Genomics Holdings Company Limited ("ACT Genomics") to Delta Electronics, Inc. (TWSE: 2308) ("Delta"). Delta is a global leader in power management and smart green solutions, as well as a provider of healthcare technologies. The transaction regarding Delta's acquisition of up to 100% ACT Genomics' shareholdings is valued at up to US$71.78 million. Prenetics, holding a majority stake in ACT Genomics, will receive a gross proceed of approximately US$46 million in cash post-closing of the transaction and subject to customary release conditions. With a cash balance of US$44 million1, this divestment bolsters Prenetics financial position, increasing its pro-forma cash reserves to approximately US$86 million2 and with $117 million pro-forma short term assets3, while maintaining a debt-free balance sheet.
ACT Genomics' expertise in clinical diagnostics and next-generation sequencing (NGS) is expected to complement Delta's existing healthcare solutions portfolio, fostering new synergies and growth opportunities in the precision medicine market.
Danny Yeung, CEO and Co-Founder of Prenetics, commented, "This transaction is a testament to the value we have built within ACT Genomics and marks an important milestone for Prenetics. We are incredibly proud of the ACT Genomics team and their contributions. We are confident that under Delta's stewardship, ACT Genomics will continue to thrive and make significant contributions to the field of genomic medicine."
Strategic Transformation: Simplified Business Model with Exceptional Growth
The divestment of ACT Genomics marks the successful completion of Prenetics' strategic transformation, addressing previous investor feedback regarding business complexity while positioning the company for accelerated growth in the high-margin consumer health market. The transaction enables Prenetics to simplify its investment thesis, enhance financial flexibility, accelerate growth focus, and optimize resource allocation.
Exceptional Consumer Health Performance Validates Strategy: Prenetics' consumer health business has demonstrated remarkable momentum with:
<ul>
<li>Q1 2025 revenue of $14.4 million representing a 336.5% increase year-over-year &nbsp;</li>
<li>Management increased full-year 2025 revenue guidance to US$80-100 million (excluding ACT Genomics), up from the previous range of US$73-85 million, demonstrating confidence in the core business trajectory. &nbsp;</li>
</ul>
IM8 Health Success Story: The flagship IM8 brand, has achieved extraordinary success in just six months since launch with:
<ul>
<li>Over 55,000 customers acquired, 4.9 million servings delivered &nbsp;</li>
<li>Industry-leading 91% subscription rate, US$109 average order value, &nbsp;</li>
<li>Global expansion to 31 countries &nbsp;</li>
<li>Q1 revenue of US$5.7 million and projected Q2 revenue of US$8.5 million (50% quarter-over-quarter growth). &nbsp;</li>
</ul>
Focused Portfolio of Leading Consumer Health Brands: Post-divestment, Prenetics operates three complementary consumer health brands: IM8 (premium health supplements brand), CircleDNA (leading direct-to-consumer DNA testing platform), and Europa (one of the largest sports nutrition distribution companies in the United States).
Enhanced Financial Position Enables Significant Opportunities for Shareholder Value
The ACT Genomics divestment significantly strengthens Prenetics' financial foundation with pro-forma cash reserves of approximately US$86 million and pro-forma cash and short−term assets of US$117 million. The company maintains its debt-free balance sheet with zero debt.
Strategic Investment Portfolio: Beyond its operating businesses, Prenetics maintains a valuable 35% stake in Insighta, an early cancer detection company. Based on Tencent's recent investment in Insighta, this stake is valued at $70 million, representing significant additional value for Prenetics shareholders.
Innovation Leadership: With a robust cash position and accelerating business fundamentals, Prenetics is strategically positioned to explore cutting-edge treasury management approaches, including digital asset adoption and Bitcoin treasury strategies.

Asset Sales

Scholar Rock Unloads Genomics Unit for $46M, Boosting Cash Reserves and Refocusing on Consumer Health Growth

Citigroup analyst Vicky Wei downgrades Smart Share Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EM#NASDAQ">EM</a>) from Buy to Neutral and raises the price target from $1 to $1.25.

Citigroup Downgrades Smart Share Global to Neutral, Raises Price Target to $1.25

Needham analyst Ami Fadia reiterates Immuneering (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRX#NASDAQ">IMRX</a>) with a Buy and maintains $9 price target.

Reiteration

IMRX

Needham Reiterates Buy on Immuneering, Maintains $9 Price Target

Citigroup analyst Andres Cardona initiates coverage on Loma Negra Cia Industria (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOMA#NYSE">LOMA</a>) with a Buy rating and announces Price Target of $16.

Comments

Baosheng Media Gr

Noticias

Últimas noticias sobre Baosheng Media Gr (NASDAQ:BAOS) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL